Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.
Kawakita D, Tada Y, Imanishi Y, Beppu S, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Shimizu A, Sato Y, Fushimi C, Takase S, Okada T, Sato H, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Shimura T, Hanazawa T, Murakami S, Nagao T. Kawakita D, et al. Among authors: sato y, sato h. Oncotarget. 2017 Jan 3;8(1):1083-1091. doi: 10.18632/oncotarget.13565. Oncotarget. 2017. PMID: 27894101 Free PMC article.
Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification.
Takase S, Kano S, Tada Y, Kawakita D, Shimura T, Hirai H, Tsukahara K, Shimizu A, Imanishi Y, Ozawa H, Okami K, Sato Y, Sato Y, Fushimi C, Okada T, Sato H, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Hanazawa T, Chazono H, Osamura RY, Nagao T. Takase S, et al. Among authors: sato y, sato h. Oncotarget. 2017 Aug 2;8(35):59023-59035. doi: 10.18632/oncotarget.19812. eCollection 2017 Aug 29. Oncotarget. 2017. PMID: 28938615 Free PMC article.
Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.
Shimura T, Tada Y, Hirai H, Kawakita D, Kano S, Tsukahara K, Shimizu A, Takase S, Imanishi Y, Ozawa H, Okami K, Sato Y, Sato Y, Fushimi C, Takahashi H, Okada T, Sato H, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Ando M, Kohsaka S, Hanazawa T, Chazono H, Kadokura Y, Kobayashi H, Nagao T. Shimura T, et al. Among authors: sato y, sato h. Oncotarget. 2017 Dec 4;9(2):1852-1867. doi: 10.18632/oncotarget.22927. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416736 Free PMC article.
The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.
Urano M, Hirai H, Tada Y, Kawakita D, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Sato Y, Saigusa N, Nakaguro M, Hanazawa T, Nagao T. Urano M, et al. Among authors: sato y, sato h. Histopathology. 2018 Dec;73(6):943-952. doi: 10.1111/his.13706. Epub 2018 Sep 25. Histopathology. 2018. PMID: 29993139
Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model.
Nakaguro M, Sato Y, Tada Y, Kawakita D, Hirai H, Urano M, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Saigusa N, Takahashi H, Ando M, Hanazawa T, Nagao T. Nakaguro M, et al. Among authors: sato y, sato h. Am J Surg Pathol. 2020 Apr;44(4):526-535. doi: 10.1097/PAS.0000000000001413. Am J Surg Pathol. 2020. PMID: 31764219
The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma.
Hirai H, Tada Y, Nakaguro M, Kawakita D, Sato Y, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Okamoto I, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Saigusa N, Takahashi H, Ando M, Urano M, Hanazawa T, Nagao T. Hirai H, et al. Among authors: sato y, sato h. Virchows Arch. 2020 Aug;477(2):291-299. doi: 10.1007/s00428-020-02777-w. Epub 2020 Feb 26. Virchows Arch. 2020. PMID: 32103349 Free PMC article.
Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients.
Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K, Hanyu K, Masubuchi T, Tada Y, Miura K, Omura G, Sawabe M, Kawakita D, Yamashita T. Matsuki T, et al. Among authors: sato h. Cancers (Basel). 2020 Nov 18;12(11):3427. doi: 10.3390/cancers12113427. Cancers (Basel). 2020. PMID: 33218183 Free PMC article.
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Sato H, Tsukahara K, Okamoto I, Katsube Y, Shimizu A, Kondo T, Hanyu K, Fushimi C, Okada T, Miura K. Sato H, et al. Acta Otolaryngol. 2019 Feb;139(2):201-205. doi: 10.1080/00016489.2018.1551623. Epub 2019 Feb 22. Acta Otolaryngol. 2019. PMID: 30794080
Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
Matsuki T, Okamoto I, Fushimi C, Sawabe M, Kawakita D, Sato H, Tsukahara K, Kondo T, Okada T, Tada Y, Miura K, Omura G, Yamashita T. Matsuki T, et al. Among authors: sato h. Cancer Med. 2020 Jul;9(14):5015-5024. doi: 10.1002/cam4.3124. Epub 2020 May 22. Cancer Med. 2020. PMID: 32441463 Free PMC article.
10,138 results
You have reached the last available page of results. Please see the User Guide for more information.